Navigation Links
KaloBios Announces Fiscal Year 2012 Financial Results
Date:3/27/2013

SOUTH SAN FRANCISCO, Calif., March 27, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced financial results for fiscal year 2012.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)  Financial Highlights ($ in millions, except per share data, unaudited)FY 2012FY 2011Percent ChangeContract Revenue$
.1$   20.3-70%Research & Development Expense24.518.532%General & Administrative Expense5.14.028%GAAP Net Loss(23.5)(2.2)100%+GAAP Net Loss per Share (basic and diluted)$ (11.22)$  (1.15)100%+Cash, cash equivalents and marketable securities$
20.3$   17.814%GAAP net loss for the year ended December 31, 2012 was $23.5 million ($11.22 per share) compared to GAAP net loss of $2.2 million ($1.15 per share) for the year ended December 31, 2011.

Contract Revenue was $6.1 million for the fiscal year 2012 compared to $20.3 million for 2011.  The decrease in contract revenues was due to the completion of all substantive performance obligations related to research support activities under our agreement with Sanofi Pasteur (Sanofi), the vaccines division of Sanofi Group.

Research and Development (R&D) expenses were $24.5 million for the fiscal year 2012 compared to $18.5M in 2011. R&D expense increased during 2012 due to increased clinical trial activity compared with the prior period.  General and administrative (G&A) expenses were $5.1 million for the fiscal year 2012 compared to $4.0M in 2011. G&A expense increased in 2012 due to higher legal, accounting and consulting costs.  We expect operating expenses to continue to increase during 2013 as we further develop our clinical programs and incur expenses associated with being a public company.

As of December 31, 2012, KaloBios had cash, cash equivale
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. CfPIE Announces Advisory Board to Support Continued Life Sciences Training Alignment with Industry Regulations
2. SoundConnect Announces Audio Conferencing Capacity Upgrades
3. BMI Surplus Announces Sale of Thermal Vacuum Space Simulation Chamber
4. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
5. National Brain Tumor Society Announces Launch of Defeat GBM Research Collaborative
6. Regenerative Medicine Company, Eqalix, Announces Grant from Nanotechnology Institute in Philadelphia, Pennsylvania
7. Probiotics Are in More Than Just Yogurt: Probiotic Action Announces 5 New Items Containing the Healthy Bacteria
8. Synedgen Announces Issuance of Patent to Optimize Animal Health
9. Piramal Imaging Announces the Acceptance for Review of [18F] florbetaben by the FDA and EMA for the Visual Detection of beta-amyloid in Alzheimers Disease
10. Probiotic Action Announces Probiotics Pending Listing on EU Foods
11. Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 OMICS Group’s ... techniques during 18-20 August, 2014 at Double Tree by ... the recent developments in Analytical & Bioanalytical research methods ... , Speaking on this occasion, Dr. Srinubabu Gedela, MD ... Acta conference is a remarkable one in bringing a ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... According to the International Atomic Energy Agency (IAEA) ... terrorists acquiring sufficient quantities of plutonium or highly ... explosive device. The IAEA also notes that most ... quantities, which can be challenging to detect with ... study appearing this week in the Journal ...
Breaking Biology Technology:A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Sensitive detection method may help impede illicit nuclear trafficking 2
... Bio-Technology to Present at Rodman and Renshaw,s Annual Global Investment Conference on... -- HARBIN, China, Sept. ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
... 7 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... for human disease, announced today that it will be participating ... New York.   Dr. Arthur T. Sands , president and ... on Monday, September 13, 2010 at 10:20 a.m. Eastern Time. ...
... AMLN ) will be presenting at the Morgan Stanley Global ... ET / 7:55 a.m. PT in ... Tuesday, September 14, 2010 at 11:30 a.m. ET / 8:30 ... president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate ...
Cached Biology Technology:Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 2Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 3Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 4Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 5Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 6Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010 7Lexicon to Present at Morgan Stanley Global Healthcare Conference 2
(Date:7/10/2014)... HUNTINGTON, W.Va. The Marshall Institute for Interdisciplinary ... Edwards School of Medicine today announced they will ... develop potential anti-cancer drugs. , Under the agreement ... partners will share the costs and risks of ... also will jointly own any intellectual property and ...
(Date:7/10/2014)... Endomedix, a start-up company housed at NJIT,s business incubator, ... spray-on gel that surgeons will use to staunch bleeding ... onto a surgical site, and the natural bio-polymer solutions ... the patient within 30 seconds. , The gel ... It will translate into less time for the patient,s ...
(Date:7/10/2014)... diseases, such as Alzheimer,s disease, type 2 diabetes, ... common trait that proteins aggregate into long fibers ... have found that neither the amylin monomer precursors ... evidence using two-dimensional infrared (2D IR) spectroscopy has ... pathway that may explain toxicity, opening a window ...
Breaking Biology News(10 mins):Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2New technology reveals insights into mechanisms underlying amyloid diseases 2
... Va. (March 31, 2010) Healthy pre-and ... SE5-OH containing Natural S-equol, a novel soy germ-based ... symptoms, had measures of reproductive hormones that stayed ... safety data were presented at the American Medical ...
... available in Spanish . , Asian wheat may ... varieties against Fusarium graminearum fungi that cause ... Research Service (ARS) plant molecular biologist Guihua Bai, the FHB ... on the Chinese wheat variety Sumai 3 and a few ...
... When David Beckham limped off the pitch, thereby ending ... this summer, sports injuries and rehabilitation techniques were once ... media attention paid to one player,s Achilles tendon is ... as a field of research. Now Paul Comfort and ...
Cached Biology News:Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 2Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 3Soy germ-based supplement SE5-OH containing natural S-Equol examined for safety, hormonal influence 4Diverse wheat tapped for antifungal genes 2Sports rehabilitation and injury prevention 2
MOUSE ANTI RAT RT1Ac Immunogen: PHA activated rat lymphocytes...
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
Biology Products: